DE68908913T2 - Faktor XIII zur Vorbeugung von intraventrikulären Blutungen. - Google Patents

Faktor XIII zur Vorbeugung von intraventrikulären Blutungen.

Info

Publication number
DE68908913T2
DE68908913T2 DE89102471T DE68908913T DE68908913T2 DE 68908913 T2 DE68908913 T2 DE 68908913T2 DE 89102471 T DE89102471 T DE 89102471T DE 68908913 T DE68908913 T DE 68908913T DE 68908913 T2 DE68908913 T2 DE 68908913T2
Authority
DE
Germany
Prior art keywords
factor xiii
precipitate
intraventricular
bleeding
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE89102471T
Other languages
German (de)
English (en)
Other versions
DE68908913D1 (de
Inventor
Akira Shirahata
Satoshi Tanaka
Kenichiro Tsumura
Minoru Uchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of DE68908913D1 publication Critical patent/DE68908913D1/de
Publication of DE68908913T2 publication Critical patent/DE68908913T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE89102471T 1988-02-24 1989-02-14 Faktor XIII zur Vorbeugung von intraventrikulären Blutungen. Expired - Lifetime DE68908913T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤

Publications (2)

Publication Number Publication Date
DE68908913D1 DE68908913D1 (de) 1993-10-14
DE68908913T2 true DE68908913T2 (de) 1994-01-27

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89102471T Expired - Lifetime DE68908913T2 (de) 1988-02-24 1989-02-14 Faktor XIII zur Vorbeugung von intraventrikulären Blutungen.

Country Status (12)

Country Link
US (1) US5114916A (cg-RX-API-DMAC7.html)
EP (1) EP0330049B1 (cg-RX-API-DMAC7.html)
JP (1) JPH01216939A (cg-RX-API-DMAC7.html)
KR (1) KR0137476B1 (cg-RX-API-DMAC7.html)
AT (1) ATE94070T1 (cg-RX-API-DMAC7.html)
AU (1) AU613154B2 (cg-RX-API-DMAC7.html)
CA (1) CA1332352C (cg-RX-API-DMAC7.html)
DE (1) DE68908913T2 (cg-RX-API-DMAC7.html)
DK (1) DK174978B1 (cg-RX-API-DMAC7.html)
ES (1) ES2059588T3 (cg-RX-API-DMAC7.html)
IE (1) IE63656B1 (cg-RX-API-DMAC7.html)
PT (1) PT89802B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
JPH07502734A (ja) * 1991-12-31 1995-03-23 ザイモジェネティクス，インコーポレイティド 血液損失を減少する方法および組成物
DE69328228T2 (de) * 1992-04-21 2000-12-21 Ajinomoto Co., Inc. Wundheilmittel
DK0669834T3 (da) * 1992-11-12 2000-04-17 Zymogenetics Inc Anvendelse af topisk påført faktor Xlll til inhibering af blødning
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
EP1784415A2 (en) * 2004-08-27 2007-05-16 Novo Nordisk Health Care AG Purification of factor xiii polypeptides from biological materials
JP5086093B2 (ja) * 2004-11-23 2012-11-28 ジモジェネティクス、インコーポレイテッド 組換え型ヒトｘｉｉｉ因子の精製
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
JP5033177B2 (ja) * 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
NZ597089A (en) 2009-06-25 2014-05-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
DK175919B1 (da) * 1986-09-19 2005-06-27 Univ Washington Ekspression af biologisk aktiv faktor XIII

Also Published As

Publication number Publication date
US5114916A (en) 1992-05-19
KR0137476B1 (ko) 1998-06-01
AU613154B2 (en) 1991-07-25
EP0330049A3 (en) 1991-01-30
JPH01216939A (ja) 1989-08-30
IE63656B1 (en) 1995-05-31
IE890580L (en) 1989-08-24
EP0330049B1 (en) 1993-09-08
PT89802A (pt) 1989-10-04
DK83889A (da) 1989-08-25
EP0330049A2 (en) 1989-08-30
DK174978B1 (da) 2004-04-05
ES2059588T3 (es) 1994-11-16
AU3024389A (en) 1989-08-24
ATE94070T1 (de) 1993-09-15
DE68908913D1 (de) 1993-10-14
DK83889D0 (da) 1989-02-23
JPH0378850B2 (cg-RX-API-DMAC7.html) 1991-12-17
CA1332352C (en) 1994-10-11
PT89802B (pt) 1994-04-29
KR890012659A (ko) 1989-09-18

Similar Documents

Publication Publication Date Title
DE68908913T2 (de) Faktor XIII zur Vorbeugung von intraventrikulären Blutungen.
US4340589A (en) Antithrombin preparation and process for the production thereof
DE69713485T2 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
DE60024415T2 (de) Glycin-betain zumr antithrombotischen gebrauch
EP0052827B1 (de) Verfahren zur Herstellung von Blutgerinnungsfaktoren und danach hergestellte Präparation der Faktoren II und VII
EP0053338A2 (de) Verfahren zur Herstellung von Blutgerinnungsfaktoren
CH664495A5 (de) Pharmazeutische formulierung.
US5561109A (en) Method for the healing of wounds caused by corneal injury
EP0430200A1 (de) Arzneimittel zur subkutanen oder intramuskulären Applikation enthaltend Polypeptide
DE69321007T2 (de) Zusammensetzung zur Stabilisierung von Blutplasma im Laufe der Pasteurisation und Pasteurisationsverfahren unter Verwendung dieser Zusammensetzung
US6720011B1 (en) Injectable composition for cancer treatment
EP0625908B1 (de) Antidot für hirudin und synthetische thrombininhibitoren
EP0514367B1 (de) Arzneimittel enthaltend Protein C
DE69326627T2 (de) Therapeutisches Mittel gegen drohenden Abortus
DE3876817T2 (de) Anwendung des humanblut-koagulationsfaktors-xiii zur behandlung von colitis gravis.
JPH01151514A (ja) 神経疾患治療・予防剤
DE69330960T2 (de) Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil
DE69431430T2 (de) Faktor XIII zur Behandlung von Hautwunden
DE69113437T2 (de) Therapeutische Mittel für diabetisches Gangrän.
EP0119990A2 (de) Verfahren zur Herstellung von therapeutisch verabreichbaren, in Endbehältern abgefüllten Plasmaderivaten
DE69905489T2 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE69117920T2 (de) Zusammensetzung zur stabilisierung von blutplasma im laufe der pasteurisation
DE68913212T2 (de) Ein reines faktor i-protein und verfahren zur herstellung.
Burrage et al. Maintenance cortisone in severe bronchial asthma
DE60128130T2 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a

Legal Events

Date Code Title Description
8364 No opposition during term of opposition